Study Trends Online Professional Activities and Reveals Specialty-specific Marketing Opportunities

Manhattan ResearchManhattan Research, a healthcare market research services firm, announced the leading pharmaceutical product website destinations for physicians from its new physician research study, "ePharma Physician® v7.0: The Future of Professional eMarketing.". Manhattan Research recently hosted a webcast discussing highlights of the ePharma Physician® v7.0 research.

Top 10 Pharma Product Websites Among Physicians in 2007
Ranked by Number of U.S. Primary Care Physician Visitors

1 Januvia
2 Singulair
3 Advair
4 Chantix
5 Adderall XR
6 Byetta
7 Gardasil
8 Vytorin
9 Avandia
10 Concerta

Source: ePharma Physician® v7.0, Manhattan Research, LLC

"The latest research reveals physician site traffic is spread among product sites of new and early launch stage treatments, those with clinical news coverage, and consistent with years past, products with a significant consumer advertising component," states Mark Bard, president of Manhattan Research. He continues, "We have seen these product sites evolve into brand gateways with visitation from physicians, healthcare professionals, and consumers and with the majority of the top 10 product sites changing from year to year, there is clearly a need among physicians for the most upto- date product information."

For the sixth consecutive year, Manhattan Research has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit. In-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters and society sites is now available as part of the ePharma Physician® v7.0 advisory service.

ePharma Physician® v7.0 reveals the relevant market share and physician satisfaction for 300+ leading pharmaceutical product websites. A complete list of available product sites is available at www.manhattanresearch.com/ePP.aspx

ePharma Physician® v7.0 also includes the following specialist segments in the research: Allergy and Immunology, Cardiology (Cardiovascular Surgery and Interventional Cardiology), Dermatology, Emergency Medicine, Endocrinology, Family Medicine/General Practice, Gastroenterology, Infectious Disease or HIV physician, Internal Medicine, Nephrology, Neurology, OB/GYN, Oncology–Hematology & Hematology, Ophthalmology, Pediatrics, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery (General and Orthopedic), and Urology.

About Manhattan Research
In addition to ePharma Physician®, Manhattan Research conducts numerous research studies among physicians and consumers in the United States and in Europe. Each study serves a unique purpose and focuses on different aspects of information technology adoption. Broad research is complemented by targeted analysis among more than 50 consumer therapeutic segments and 25 physician specialist segments. For further information, please visit www.manhattanresearch.com

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]